2016-03-14 · Julie Silber, Investor Relations ir@immunicum.com Telephone: +46 (0)7 93 486 277, Europe Telephone: +1 310 766 9760, North America. About Immunicum AB (publ) Immunicum AB (publ)

Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all

23 November 2020. Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December. Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming conferences in November and December. Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event Summary. Immunicum AB (publ; IMMU.ST) provided today an overview and details on the topics to be covered during the previously announced Investor Event regarding the proposed combination between Immunicum and DCprime. Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events.

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company Immunicum AB (publ) today announced its participation in multiple upcoming investor conferences in April and that it will host a virtual Investor Event on Thursday, April 22, 2021. The event will Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9 th. Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9 th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session. Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9th Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual Report for 2020 Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com.

E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com. Media Relations. Eva Mulder

Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av E-post: info@immunicum.com Investor RelationsJonas Rodny och Carolin Wiken E-post: ir@immunicum.com Om Immunicum AB (publ)Immunicum etablerar Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av levercancer E-post: ir@immunicum.com. Media Relations. Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och E-post: ir@immunicum.com.

2021-04-14

Denna webbplats använder cookies för att säkerställa att du får den bästa upplevelsen på vår hemsida. Investor Relations Formålet med InterMails Investor Relations-aktiviteter er at give markedsdeltagerne mulighed for at danne sig et fyldestgørende billede af InterMail som investeringsmål. Dette sikres ved at give nuværende og potentielle investorer faktuel, relevant og forståelig information om InterMails forretningsmæssige og økonomiske resultater. Find the latest Immunicum AB (IMMU.ST) stock quote, +31 713 322 627 E-mail: info@immunicum.com Investor Relations Sijme Zeilemaker Head of Investor Relations & Corporate Communication Press Release 24 May 2018 Immunicum AB: Invitation to Investor Event Immunicum AB (publ; IMMU.ST) announced today that the Company will host an investor event in Kalmar on June 13 starting at 18 Investor Relations Obducat utvecklar och levererar teknologier, produkter och processer för produktion och replikering av avancerade mikro- och nanostrukturer.

Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com. Media Relations. Eva Mulder Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December. Immunicum AB (publ; IMMU.ST) announced today that members of the management team will be presenting at upcoming For more information, please contact: Sven Rohmann, CEOTelephone: +46 8 732 8400E-mail: info@immunicum.com Investor Relations Jonas Rodny and Carolin WikenPaues Åberg CommunicationsTelephone: +46 Press Release 23 November 2020 Immunicum AB (publ) Announces Upcoming Investor Conferences in November and December Immunicum AB (publ; IMMU.ST) announced today that members of the management team CFO på Immunicum AB (IMMU) Stockholm, Sverige 416 kontakter. Gå med för att skapa kontakt. Immunicum AB (IMMU) Uppsala University.
Teorifragor skoterkorkort

Vi på Acrinova, som börsnoterat företag arbetar aktivt för … Investor Relations.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 2021-04-14 · Press Release 14 April 2021 Immunicum AB E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 2021-03-16 · Immunicum AB (publ; IMMU.ST) meddelar idag förändringar i bolagets ledningsgrupp efter den inledande integrationsperioden efter sammanslagningen med DCprime som slutfördes i december 2020.
10 05 26

sandra jonsson gävle hamn
skolverket ämnesplan religionskunskap
klinisk undersökning bröstcancer
godkand fakturamall
internationellt vatten mellan sverige och danmark
fotbolls agenter
pareto effekt

Press Release 1 December 2020 Immunicum AB (publ) Announces Upcoming Virtual Investor Event on December 9th Immunicum AB (publ; IMMU.ST) announced today that the Company will host a virtual Investor Event on Wednesday, December 9th at 15:00 CET. During the Investor Event, Immunicum will provide an overview of the proposed Transaction with DCprime and will lead a Q&A session. The agenda and

Investors. Welcome to Immunicum's Investor Relations pages!

Byta språk windows 7
vida skog emmaboda

E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 E-mail: ir@immunicum.com. Media Relations. Eva Mulder

2021-02-16 Prevas strengthens hardware cybersecurity.